StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) stock

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.63−0.05 (-7.21%)

Close on Nov 17, 2026Market cap $23.84MP/E –Yield –

Metagenomi Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Metagenomi Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$85.49M. For fiscal 2025 it was -$88.89M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$88.89M–
FY2024Dec 31, 2024-$109.07M–
FY2023Dec 31, 2023-$91.41M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.51M–
Q1 FY2026Mar 31, 2026-$21.18M–
Q4 FY2025Dec 31, 2025-$23.55M–
Q3 FY2025Sep 30, 2025-$21.25M–
Q2 FY2025Jun 30, 2025-$21.25M–
Q1 FY2025Mar 31, 2025-$22.84M–
Q4 FY2024Dec 31, 2024-$26.28M–
Q3 FY2024Sep 30, 2024-$26.64M–
Q2 FY2024Jun 30, 2024-$26.31M–
Q1 FY2024Mar 31, 2024-$29.85M–
Q4 FY2023Dec 31, 2023-$20.59M–
Q3 FY2023Sep 30, 2023-$23.73M–
Q2 FY2023Jun 30, 2023-$26.09M–
Q1 FY2023Mar 31, 2023-$21.00M–

More Metagenomi Therapeutics figures

See a number that looks wrong?